World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ANZCTR
Last refreshed on: 13 January 2020
Main ID:  ACTRN12615000757516
Date of registration: 21/07/2015
Prospective Registration: No
Primary sponsor: Dr. I Wayan Weta
Public title: The effect of canola oil diet supplementation on fatty liver in young obese females in Bali
Scientific title: The effect of canola oil diet supplementation on liver steatosis, lipid accumulation product, and fatty liver index in young obese females in Bali
Date of first enrolment: 12/05/2013
Target sample size: 74
Recruitment status: Completed
URL:  https://anzctr.org.au/ACTRN12615000757516.aspx
Study type:  Interventional
Study design:  Purpose: Treatment; Allocation: Randomised controlled trial; Masking: Blinded (masking used);  
Phase:  Not Applicable
Countries of recruitment
Indonesia
Contacts
Name: Dr I Wayan Weta   
Address:  Faculty of Medicine, Udayana University Jl. PB Sudirman, Denpasar, Bali 80232 Indonesia
Telephone: +6281337005360
Email: wayan_weta06@yahoo.co.id
Affiliation: 
Name: Dr I Wayan Weta   
Address:  Faculty of Medicine, Udayana University Jl. PB Sudirman, Denpasar, Bali 80232 Indonesia
Telephone: +6281337005360
Email: wayan_weta06@yahoo.co.id
Affiliation: 
Key inclusion & exclusion criteria
Inclusion criteria: Obese (BMI > 25kg/m2)
Female
Age 18 - 25 years old
Unmarried
Not necessarily to have liver steatosis

Exclusion criteria: Taking pharmacologic and/or herbal regiment to loose weight
Daily intake of antioxidant, vitamins, minerals or other food supplement
Under treatment of chronic disease
Under influence of corticosteroidand/or other anti-inflammatory medicine


Age minimum: 18 Years
Age maximum: 25 Years
Gender: Females
Health Condition(s) or Problem(s) studied
Obesity;Liver steatosis;
Obesity
Liver steatosis
Oral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Diet and Nutrition - Obesity
Intervention(s)
30 ml emulsion consisted of 10 g canola oil (2000 mg linoleic acid (LA), and 1000 mg a-linolenic acid (ALA), n-6:n-3 PUFA ratio 2:1). This intervention was administered once daily. The duration of the intervention was 12 weeks. The mode of administration was oral syrup, monitored weekly by bringing back the bottles. All subjects were recommended for restricted daily energy intake below 1500 kcal and exercise once a week. Diet consultation and exercise were conducted weekly, at the same time of the monitoring.

Primary Outcome(s)
Changes of lipid accumulation product, assessed by an algorithm based on waist circumference and triglyceride.[At 0, 6 and 12 weeks]
Changes in liver steatosis, assessed by ultrasonography.[At 0 and 12 weeks]
Changes of fatty liver index, assessed by an algorithm based on BMI, waist circumference, triglyceride and gamma-glutamyl transferase.[At 0, 6 and 12 weeks]
Secondary Outcome(s)
Changes of TNF alpha and IL-10 levels will be determined, measured by ELISA.[At 0, 6 and 12 weeks]
Anthropometry changes will be assessed, determined by changes in BMI and waist cricumference.[At 0, 6 and 12 weeks]
Secondary ID(s)
None
Source(s) of Monetary Support
Indonesian Danone Institute Foundation
Secondary Sponsor(s)
Ethics review
Status: Approved
Approval date:
Contact:
Research Ethics Committee of Udayana University/Sanglah Hospital
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history